Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements

Questions Remain Around Long-Term Use

PET CT scan of Human Brain (Axial view Positron Emission Tomography) — PET scans, MRI monitoring and infusions complicate treatment with anti-amyloid antibodies • Source: Shutterstock

Related Content

Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year

Jan 06 2023

Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent

May 03 2023

Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

Jul 17 2023

Leqembi Treatment Infrastructure: If Medicare Pays For It, They Will Come

Jul 08 2023

Eisai/Biogen’s Leqembi Will See Broadened Access To Majority Of Patients

Jul 07 2023

Clearing Amyloid Provides Alzheimer’s Benefit, But With Risks That Need Careful Management

Dec 08 2022

Related Companies

Eisai Co., Ltd.

Biogen, Inc.

Eli Lilly and Company

Mayo Clinic

University of Southern California

Additional Topics

Launches Market Access Drug Safety Commercial Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window